ESC Congress 2013: Predicting Treatment Success in Atrial Fibrillation

The Particulars: The validity of delayed enhancement MRI (DE-MRI) in staging atrial fibrosis and helping determine treatment success in patients with atrial fibrillation (AF) has not been well-defined.

Data Breakdown: Among 260 patients with AF, study investigators performed high resolution DE-MRI up to 30 days before scheduled ablation to determine the presence and extent of atrial fibrosis. Post-ablation DE-MRI was performed at 90-days follow-up in 177 of the subjects to determine the extent of residual ablation. Pre-ablation atrial fibrosis stage and post-ablation residual fibrosis emerged as independent predictors of successful ablation. Risk of recurrent symptoms increased by 6.3% for every increased percentage of pre-ablation fibrosis and by 8.2% for ever percentage of residual fibrosis.

Take Home Pearls: DE-MRI prior to ablative treatment appears to help stage atrial fibrosis and predict the success of treatment in patients with AF. Pre-ablation fibrosis stage and post-ablation residual fibrosis appear to predict successful ablation or recurrent symptoms.


From our CME partner, AKH Inc.

CME: Lipids and Cardiovascular Disease
CME Credit: 1.0 hour activity

The content of this activity was initially presented live at the 2014 ISSFAL Congress held in Stockholm, Sweden.  Topics Include Mediterranean Diet, Milk Fat Globule Membrane (MFGM), DHA Fatty Acid, and Omega-3 Index in Heart Failure Patients.

eMedia - Cardiology




Physician's Weekly for Current Medical News, Events & Issues